文献速递毛发、甲与色素性疾病

螺内酯联合低剂量口服米诺地尔治疗成年女性脱发的安全性与耐受性:回顾性队列研究

Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study.
PubMed 文献 · J Am Acad Dermatol · 2026-02-05

该回顾性队列纳入432例接受螺内酯联合低剂量口服米诺地尔治疗的成年女性脱发患者,不良反应发生率为37.7%。多毛症最常见(12.3%),其次为头晕/体位性低血压(12.0%);同时启用两药使多毛症风险降低64.8%,合用≥1种影响血压药物使体位性效应风险增加。

要点

  • 联合治疗不良反应多为轻度,46.0%无需调整方案,调整多在门诊完成。
  • 同时启用螺内酯与米诺地尔可能降低多毛症风险,且不增加低血压相关效应。
  • 合用≥1种影响血压药物时体位性低血压症状风险升高,需关注。

核心结论

  • 联合治疗的不良反应通常较轻,多在门诊处理。
  • 合用≥1种影响血压药物增加低血压相关症状风险。
  • 同时启用可能降低多毛症风险,不增加低血压相关效应。

研究设计与样本

  • 回顾性队列研究,纳入432例≥18岁因脱发接受联合治疗的女性。

主要发现

  • 不良反应发生率为37.7%(n=163)。
  • 多毛症最常见(n=53,12.3%),其次为头晕/头昏/体位性低血压(n=52,12.0%)。
  • 同时启用使多毛症风险降低64.8%(OR 0.35;95%CI 0.13-0.94;P=.037)。
  • 合用≥1种影响血压药物增加体位性效应风险(OR 3.29;95%CI 1.65-6.58;P=.001)。
  • 46.0%病例治疗方案未调整,调整者94.3%在门诊进行。

关键数值与推荐

  • 出现不良反应时平均螺内酯剂量87.6±51.4 mg,低剂量口服米诺地尔平均1.8±1.1 mg。
  • 剂量与治疗启用模式未显著增加血压相关效应风险。

临床怎么用

  • 联合治疗可在门诊管理,多数不良反应轻微。
  • 合用影响血压药物时应警惕体位性低血压症状。
  • 同时启用两药可能减少多毛症且不增加低血压相关效应。

局限性

  • 回顾性描述性研究,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spironolactone and oral minoxidil are effective female alopecia monotherapies. Combination therapy is commonly used, though safety and tolerability data are limited. OBJECTIVE: To assess safety and tolerability by adverse effect incidence. METHODS: Retrospective cohort study conducted in females aged ≥18 taking combination therapy for hair loss. RESULTS: A total of 432 patients were included. Average spironolactone and low-dose oral minoxidil doses at time of adverse drug effects were 87.6 ± 51.4 mg and 1.8 ± 1.1 mg, respectively. Adverse effect incidence was 37.7% (n = 163). Hypertrichosis was most common (n = 53, 12.3%) followed by dizziness/lightheadedness/orthostasis (n = 52, 12.0%). Simultaneous initiation was observed to reduce hypertrichosis risk by 64.8% (odds ratio: 0.35; 95% confidence interval 0.13-0.94; P = .037). Concurrent use of ≥1 additional blood pressure-altering medications increased orthostatic effects risk (odds ratio: 3.29; 95% confidence interval: 1.65-6.58; P = .001). Dosage and treatment initiation pattern did not significantly increase risk of blood pressure effects. In 46.0% of cases, the therapeutic regimen was unmodified. When adjustments were made, they largely occurred in the outpatient setting (94.3%). LIMITATIONS: Retrospective descriptive study lacking a control group. CONCLUSION: Adverse effects from combination therapy are generally mild and managed outpatient. Concomitant use of ≥1 blood pressure-altering drugs increases risk of hypotension-related symptoms. Simultaneous initiation may reduce risk of hypertrichosis without increasing risk of hypotension-related effects.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Dewey E, Salloum L, Gregoire S, et al. Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study. J Am Acad Dermatol. 2026. PMID: 41654020. doi:10.1016/j.jaad.2026.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。